In the last few years, psychedelic medicines for mental health diseases such as depression, anxiety, and post-traumatic stress disorder have transformed the business. The innovative therapeutics market is predicted to rise from $2 billion in 2019 to over $5 billion in 2020. Psychedelic equities have lately received coverage from Citi, Credit Suisse, Canaccord Genuity, and Cantor Fitzgerald. Biopharma companies sell a variety of pharmaceuticals to treat mental illnesses, and they see a profit potential as new treatments for depression and anxiety gain acceptance. COMPASS Pathways Plc and Atai Life Sciences N.V. are two firms that have already made a major mark in the still-small sector. In the last few months, there has been an increase in investments in psychedelic startups. Psychedelics remain a niche market in the pharmaceutical industry, despite these developments. Investors considering the business should be aware of some of the hurdles that psychedelic companies will face before realizing their full potential.
Here is Insider Monkey’s list of the 10 best psychedelic stocks to buy now. Small Pharma Inc. is ranked tenth. Over the last five days, investors have received a 14 percent return on their investment in the company’s stock. It is developing antidepressants with a short half-life. Over the last year, Revive Therapeutics Ltd. stock has returned 123 percent to investors. The company is a life sciences company that focuses on the discovery of medications for the treatment of uncommon ailments and infectious diseases, such as psychedelics. Numinus Wellness Inc. is a psychedelic-assisted psychotherapy development and delivery company. Over the last year, investors have received a 282 percent return on their investment in the company’s stock. Numinus is worth more than $165 million on the stock market. Hollister Biosciences Inc. is ranked seventh. Over the previous year, the stock has provided investors with returns of more than 78 percent. It has a market capitalization of more than $55 million and generated more than $30 million in revenue last year. Field Trip Health Ltd. is a company that focuses on psychedelic therapy development and delivery. Over the last year, the company’s stock has provided investors with returns of more than %. It is ranked number six on the list of the top ten psychedelic stocks to purchase right now. For more details, click 10 Best Psychedelic Stocks to Buy Now.
Unsplash
